Commonwealth Retirement Investments LLC Has $535,000 Stock Holdings in Abbott Laboratories $ABT

Key Points

• Commonwealth Retirement Investments LLC cut its Abbott Laboratories stake by 76.2% in the second quarter, retaining 5,893 shares valued at approximately $535,000. Institutional investors own 75.18% of Abbott’s stock.
• Abbott exceeded quarterly expectations with $1.31 in adjusted EPS and $12.59 billion in revenue, up 13% year over year. The company guided to fiscal 2026 EPS of $5.45–$5.60.
• Analysts maintain a bullish outlook, with a consensus “Moderate Buy” rating and an average price target of $118.67; Abbott also pays a quarterly dividend of $0.63 per share, yielding about 2.2%.

Commonwealth Retirement Investments LLC decreased its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 76.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,893 shares of the healthcare product maker's stock after selling 18,872 shares during the period. Commonwealth Retirement Investments LLC's holdings in Abbott Laboratories were worth $535,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in ABT. Freemont Management S.A. lifted its position in shares of Abbott Laboratories by 197.2% during the 4th quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker's stock valued at $1,341,000 after acquiring an additional 7,100 shares during the period. PFA Pension Forsikringsaktieselskab acquired a new stake in Abbott Laboratories in the fourth quarter worth $116,580,000. Thrivent Financial for Lutherans increased its stake in Abbott Laboratories by 24.3% in the fourth quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker's stock valued at $30,931,000 after purchasing an additional 48,286 shares in the last quarter. Aureus Asset Management LLC increased its stake in Abbott Laboratories by 25.0% in the first quarter. Aureus Asset Management LLC now owns 331,920 shares of the healthcare product maker's stock valued at $34,078,000 after purchasing an additional 66,422 shares in the last quarter. Finally, Concurrent Investment Advisors LLC raised its holdings in shares of Abbott Laboratories by 23.9% during the fourth quarter. Concurrent Investment Advisors LLC now owns 88,784 shares of the healthcare product maker's stock valued at $11,124,000 after purchasing an additional 17,137 shares during the period. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Stock Performance

NYSE ABT opened at $116.62 on Monday. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The firm has a market cap of $201.80 billion, a price-to-earnings ratio of 37.74, a PEG ratio of 2.26 and a beta of 0.59. The company has a fifty day moving average price of $100.08 and a 200-day moving average price of $99.98.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating analysts' consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. During the same period last year, the firm earned $1.26 earnings per share. The firm's revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities research analysts predict that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were given a dividend of $0.63 per share. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.2%. Abbott Laboratories's dividend payout ratio (DPR) is currently 81.55%.

Analyst Upgrades and Downgrades

Several analysts have recently commented on ABT shares. Piper Sandler restated an "overweight" rating and issued a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. Robert W. Baird initiated coverage on Abbott Laboratories in a research note on Wednesday, July 1st. They set an "outperform" rating and a $121.00 price target on the stock. Royal Bank Of Canada reiterated an "outperform" rating and issued a $130.00 price target on shares of Abbott Laboratories in a report on Friday, July 17th. Citigroup raised their price objective on Abbott Laboratories from $108.00 to $112.00 and gave the company a "buy" rating in a research note on Friday, July 17th. Finally, Wolfe Research upgraded Abbott Laboratories from a "peer perform" rating to an "outperform" rating and set a $130.00 price objective for the company in a report on Thursday, August 13th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat.com, Abbott Laboratories presently has a consensus rating of "Moderate Buy" and an average target price of $118.67.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott’s Instinct continuous glucose sensor is now commercially shipping in the U.S. integrated with MiniMed’s Flex automated insulin-delivery system. The partnership expands Abbott’s presence in diabetes technology and could support sensor adoption and recurring revenue. MiniMed Ships MiniMed Flex With Abbott's Smallest Instinct Sensor
• Positive Sentiment: Abbott also entered a multiyear agreement with HealthTab to distribute its Afinion 2 point-of-care analyzers through NHS-linked pharmacies in the United Kingdom. The deal may broaden access to Abbott’s HbA1c and lipid-testing products, although financial details were not disclosed. HealthTab Enters Multi-Year Collaboration Agreement with Abbott
• Neutral Sentiment: Abbott agreed to pay approximately $670 million to resolve the Gill case and claims from roughly 2,000 individuals involving specialty formulas for premature infants. The settlement resolves a portion of the litigation, including the appeal of a prior $495 million verdict, reducing uncertainty and potentially avoiding additional legal costs. Abbott denied that its products cause necrotizing enterocolitis and said regulators and medical professionals consider the formulas safe and necessary. Abbott agrees to $670 million settlement of infant formula cases
• Negative Sentiment: The settlement represents a significant cash and earnings cost and does not resolve all potential litigation related to the infant formulas. Investors may continue to assess the scope of remaining claims and the effect on Abbott’s legal reserves and profitability. Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source